markets

IceCure Medical Posts 83% U.S. Sales Growth in First Nine Months of 2026

Summarized from Earnings

IceCure Medical expanded its U.S. commercial footprint to 21 states while posting 83% year-over-year growth in domestic sales through September 2026.

IceCure Medical Posts 83% U.S. Sales Growth in First Nine Months of 2026

IceCure Medical Ltd. (NASDAQ: ICCM), an Israeli medical device company developing minimally invasive cryoablation technology, reported strong financial and operational results for the nine months ended September 30, 2026, highlighted by an 83% year-over-year increase in U.S. sales.

The Caesarea, Israel-based company also disclosed a significant expansion of its commercial reach inside the United States, growing its presence to 21 states. Cryoablation, the core technology underlying IceCure's ProSense system, destroys tumors by freezing them and is designed as a less invasive alternative to conventional surgical tumor removal.

Read more Leverage Shares Launches 2x Long Anthropic ETF as ANT Debuts on Nasdaq →

The double-digit domestic sales growth signals accelerating market penetration for the company at a time when outpatient and minimally invasive oncology procedures have drawn increased interest from both health systems and payers seeking lower-cost alternatives to open surgery. IceCure's geographic expansion to 21 states represents a broadening of the addressable U.S. market for the technology.

The nine-month results through the end of September cover a period in which the company continued building out its U.S. commercial infrastructure. No full-year guidance figures were disclosed in the announcement.

Continue reading at Earnings for the complete financial tables and management commentary.

Frequently Asked Questions

Q.What is IceCure Medical's cryoablation technology?

IceCure Medical develops minimally invasive cryoablation technology that destroys tumors by freezing them, offering an alternative to conventional surgical tumor removal.

Q.How much did IceCure's U.S. sales grow in the first nine months of 2026?

IceCure reported 83% year-over-year growth in U.S. sales for the nine months ended September 30, 2026.

Q.How many U.S. states does IceCure Medical now operate in?

As of its nine-month 2026 results, IceCure Medical had expanded its U.S. commercial presence to 21 states.

More in markets →